NCT06060613 - Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions

Tumor SkinMetastatic MelanomaMelanomaLung CancerMetastatic Lung CancerNon Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

OBX-115

"A tumor sample is obtained from each participant for autologous OBX-115 manufacture.~After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by short courses of acetazolamide."

Trial Locations (9)

10065

RECRUITING

Memorial Sloan Kettering (Melanoma/NSCLC), New York

15224

RECRUITING

Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh

32806

RECRUITING

Orlando Health Cancer Institute (Melanoma/NSCLC), Orlando

40202

RECRUITING

James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville

43210

RECRUITING

The Ohio State University, Columbus

77030

RECRUITING

M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston

90025

RECRUITING

The Angeles Clinic and Research Institute (Melanoma), Los Angeles

90033

RECRUITING

USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles

94305

RECRUITING

Stanford Cancer Institute (Melanoma/NSCLC), Stanford